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Abstract 
Background: The mechanism of action of imatinib is known to involve the Fas‑mediated apoptosis pathway. Conse‑
quently inter‑individual variations in this apoptosis pathway might be associated with imatinib response or resistance.
Methods: This study attempted to focus on eight genotypes in the apoptosis pathway including FAS (rs1800682, 
rs2229521, rs2234767 and rs2234978), FASLG (rs763110), CASP10 (rs13006529), and APAF1 (rs1439123, rs2288713) and 
analyzed their association with treatment outcomes including molecular response with 4.5 log reduction (MR4.5), fol‑
lowing imatinib therapy in 187 Korean CML patients.
Results: The GG/GA genotype in FAS (rs2234767) showed a higher rate of MR4.5 than the AA genotype (at 5 years 
59.7 vs 37.4 %, p = 0.013). Using a bootstrap procedure for internal validation we confirmed that FAS (rs2234767) cor‑
relates with MR4.5 (p = 0.050). Multivariate analysis confirmed that the FAS genotype (rs2234767) is an independent 
surrogate for MR4.5 (p = 0.019, HR 0.43, 95 % CI [0.22–0.87]).
Conclusions: The Fas/FasL signaling pathway may represent the major pathway that mediates apoptosis in CML 
treated with imatinib. SNP markers in the apoptosis pathway including FAS genotype (rs2234767) can be potential 
surrogates for predicting deeper molecular response after imatinib therapy.
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Background
Chronic myeloid leukemia (CML) is a clonal disorder 
characterized by the Philadelphia (Ph) chromosome as 
a result of translocation of chromosome 9 and 22, t(9; 
22) (q34; q11) [1]. The molecular consequence of this 
translocation is rearrangement of the BCR-ABL1 onco-
gene that encodes the chimeric bcr-abl1 protein with 
constitutive kinase activity [1]. This leads to increased 
proliferation and enhanced survival of leukemic stem 
cells (LSCs) [2]. The bcr-abl1 fusion protein enhances 
cell survival and exerts antiapoptotic activity in CML 
cells, thus mediating resistance to apoptosis [3–8]. Bcr-
abl1 induces Bcl-XL, an antiapoptotic protein, through 
STAT5 phosphorylation [9]. The bcr-abl1 fusion protein 
also blocks the mitochondrial release of cytochrome C, 
exerting anti-apoptotic activity [10, 11] and inhibits other 
proapoptotic proteins including Bad or Bim [12–15].
Imatinib is a specific Abl-tyrosine kinase inhibitor that 
inhibits cellular growth and induces apoptosis in CML 
[16]. Once imatinib binds to the bcr-abl1 oncoprotein, 
it inactivates the kinase activity and subsequent signal 
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Imatinib can also restore Bad and Bim, which are inhib-
ited by the bcr-abl1 fusion protein [12–15]. The primi-
tive quiescent Philadelphia positive LSCs are relatively 
insensitive to imatinib or other tyrosine kinase inhibitors 
(TKIs) [20, 21], so it is extremely difficult to eradicate 
them with imatinib or other TKIs.
The Fas-mediated apoptosis pathway plays an impor-
tant role in imatinib’s mechanism of action. Cells 
undergo apoptosis in response to signals through sev-
eral different mechanisms including the Fas receptor 
(Fas-R) pathway. The Fas-R is expressed on hematopoi-
etic stem cells (HSCs) in CML patients [22]. The Fas-
induced pathway can trigger apoptotic signals to both 
normal HSCs and CML cells [22]. The Fas-R is upregu-
lated by IFN-gamma and TNF-alpha on CD34+  cells 
and by IFN-alpha [23]. A recent study demonstrated that 
IFN-alpha treatment promotes proliferation of dormant 
HSCs, increasing the chance of G0 cells entering into 
the active cell division cycle [24]. IFN-alpha increases 
cell death in CML patients through the Fas-mediated 
apoptosis pathway by increasing Fas-R expression on 
LSCs and increasing their exposure to cytotoxic therapy 
including TKIs.
We postulated that inter-individual variation in the 
apoptosis pathway might be associated with imatinib 
response or resistance particularly in relation to the 
depth of molecular response (4.5 log reduction or 
MR4.5), which reflects LSC clearance by TKI therapy. We 
also attempted to identify predictive/prognostic genetic 
markers in CML patients treated with imatinib. In the 
current study, candidate genotypes were selected based 
on the literature. For SNP information was not available 
in the literature, SNPs were selected using the criteria 
of synonymous or non-synonymous SNP in exon region 
with minor allele frequency >1 %. We examined 8 apop-
tosis-associated SNPs and analyzed their association with 




This study was performed according to the declaration of 
Helsinki. The study protocol was approved by the Insti-
tutional Research Board of the Sungkyunkwan University 
School of Medicine, Seoul, Korea. The study included 187 
consecutive CML patients who started imatinib therapy 
between March 2002 and December 2008 in three cen-
tres in Korea with samples available for genotyping. Clin-
ical information was obtained by retrospective medical 
chart review. Informed written consents were obtained 
from the participants in accordance with the require-
ments of the institutional Research Board of the Sungk-
yunkwan University School of Medicine. Biospecimens 
for genotyping were obtained from archived marrow or 
peripheral blood samples taken at the time of diagnosis.
Patient evaluation and disease monitoring
Prior to imatinib therapy all patients had routine history 
taken, a physical examination, a complete blood count, 
standard baseline biochemistry tests and bone marrow 
evaluation for morphology, conventional cytogenetic 
analysis, and BCR/ABL mRNA RT-PCR. Cytogenetic 
analysis was performed using the G-banding technique. 
Patients were monitored regularly on an out-patient basis 
as follows: biweekly physical examinations, blood counts, 
and biochemistry were obtained during the first month 
of imatinib therapy, then monthly until a cytogenetic 
response was achieved, and then every 3 months there-
after. Bone marrow evaluation and/or FISH studies were 
performed every 3 months until a complete cytogenetic 
response was confirmed. Quantitative BCR/ABL mRNA 
PCR on peripheral blood was repeated every 3–4 months 
regardless of cytogenetic response. This was performed 
according to the manufacturer’s instructions using ABI 
7900 Thermal Cycler (Applied Biosystems, Foster City, 
CA, USA). ABL1 gene was used as a reference. The BCR-
ABL1 transcript level data was retrospectively compared 
and validated with those using Light Cycler. Standardiza-
tion procedure to international scale was conducted per 
recommendation [25]. Sensitivity of the assay was up to 
4.5 log reduction with minimum number of reference 
gene transcripts of 32,000 copies ABL1. Abl1 tyrosine 
kinase domain mutations were screened in any patient 
in an advanced phase of disease. Mutation screening was 
indicated in patients on imatinib who had evidence of 
treatment failure, loss of response or disease progression.
Sequenom massARRAY genotyping system
Candidate genotypes were selected as synonymous or 
non-synonymous SNPs in exon regions with a minor 
allele frequency over 0.01 or based on the literature 
review. If the frequency was not available, it was sourced 
from the Entrez SNP site (http://www.ncbi.nlm.nih.gov/
sites/entrez). The study included eight SNPs in the apop-
tosis pathway (Table 1), and their linkage disequilibrium 
plot is illustrated in Additional file 1: Figure S1.
First, genotyping was undertaken using the Seque-
nom® iPLEX platform™, according to the manufacturer’s 
instructions (http://www.sequenom.com; Sequenom 
Inc, San Diego, CA, USA). DNA was extracted using the 
QIAGEN DNA purification Kit (Gentra Systems Inc, 
Minneapolis, MN, USA). We detected SNPs by analysis 
of primer extension products generated from previously 
amplified genomic DNA using a Sequenom chip-based 
matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) mass spectrometry platform. Multiplex 
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SNP assays were designed using SpectroDesigner soft-
ware (Sequenom). Ninety-six well plates containing 
2.5 ng DNA in each well were amplified by PCR follow-
ing the specifications of Sequenom. Unincorporated 
nucleotides in the PCR product were deactivated using 
shrimp alkaline phosphatase. Allele discrimination reac-
tions were performed by adding extension primer(s), 
DNA polymerase, and a cocktail mixture of deoxynu-
cleotide triphosphates and di-deoxynucleotide triphos-
phates to each well. Mass Extend clean resin (Sequenom) 
was added to the mixture for removal of extraneous salts 
that might interfere with MALDI-TOF analysis. Primer 
extension products were then cleaned and spotted onto 
a SpectroChip. Genotypes were identified by spotting an 
aliquot of each sample onto a 96 SpectroChip (Seque-
nom), which was subsequently read by a MALDI-TOF 
mass spectrometer. Duplicate samples and negative con-
trols were included for evaluation of genotyping quality. 
Primer sequences are listed in Additional file 1: Table S1. 
Genotyping was performed at Bioneer inc., Chung won, 
Korea.
Definition of response criteria and end points
Previously defined response criteria to imatinib were 
used [26–28]. The response was determined retrospec-
tively through chart review. A hematologic response 
was defined as normalized peripheral blood cell counts 
(WBC  <10 ×  109/L and platelet  <450 ×  109/L) without 
evidence of peripheral blasts, promyelocytes, or myelo-
cytes, and without evidence of extramedullary disease 
including disappearance of palpable splenomegaly lasting 
for at least 4 weeks. Cytogenetic responses were catego-
rized as complete (CCR; 0 % Ph+ cells in marrow by con-
ventional cytogenetics or FISH), partial (1–34 % Ph+ cells 
in marrow), or minor (35–65 % Ph+ cells in marrow). A 
major cytogenetic response (MCR) was defined as the 
sum of CCR and partial cytogenetic response (0–34  % 
Ph+ cells in marrow). A major molecular response 
(MMR) was defined as less than 0.1  % of the BCR/ABL 
fusion gene transcript level on an international scale 
by quantitative PCR, and molecular response with 4.5 
log reduction (MR4.5) was defined as disappearance of 
detectable BCR/ABL fusion gene transcripts, equivalent 
to less than 0.0032 % on the international scale.
Time to treatment failure (TF) was defined as the inter-
val between initiation of imatinib therapy and occurrence 
of imatinib failure, including primary and secondary resist-
ance, (i.e. loss of response (LOR). Time of LOR was defined 
as the interval between the date of any confirmed response 
(i.e. at least partial CR or deeper response) and the date 
at which criteria for response were no longer being met, 
including: transformation from chronic phase (CP) to 
accelerated phase (AP) or blastic crisis (BC), loss of CCR/
MCR, and development of the Abelson tyrosine kinase 
domain mutation. Time to progression free survival (PFS) 
was defined as the interval between initiation of imatinib 
therapy and confirmation of progression to AP or BC, 
or death from any cause, while overall survival (OS) was 
defined as time from initiation of imatinib therapy until 
time of death from any cause or time of last follow-up. Pri-
mary resistance includes primary hematologic or cytoge-
netic response while secondary resistance includes loss of 
MCR/CCR, development of progression to advanced dis-
ease as well as development of TKD mutation.
Statistical analysis
The candidate SNPs were primarily evaluated for ade-
quacy of Hardy–Weinberg Equilibrium (HWE) using the 
Chi square test. HWE and genotype frequencies were 
calculated using Haploview software version 4.2 (Broad 
Institute, Cambridge, MA; available at http://www.broa-
dinstitute.org/scientific-community/science/programs/
medical-and-population-genetics/haploview/haploview).
Cumulative incidences of MCR, CCR, MMR, and 
MR4.5 were calculated consideration discontinuation of 
imatinib as a competing risk. Probabilities of freedom 
from LOR and TF were estimated and plotted using 
the Kaplan–Meier method. Probabilities of OS and PFS 
Table 1 Summary of the candidate gene single nucleotide polymorphisms involved in the apoptosis pathway
m minor allele, M major allele, MAF minor allele frequency, HWE Hardy–Weinberg equilibrium
Gene Gene description Chromosome SNP ID Allele (m/M) Call rate (%) MAF HWE p value
APAF1 Apoptotic peptidase activating factor 1 12 rs1439123 C/T (Intron) 100 0.04 1.00
12 rs2288713 G/T (Intron) 100 0.27 0.71
CASP10 Caspase 10, apoptosis‑related cysteine peptidase 2 rs13006529 A/T (Leu → Ile) 100 0.18 1.00
FASLG Fas ligand (TNF receptor superfamily member 6) 1 rs763110 T/C 98.4 0.29 0.98
FAS Fas cell surface death receptor 10 rs1800682 T/C (Intron) 93.6 0.48 0.002
10 rs2229521 G/A(Thr → Thr) 100 0.01 1.00
10 rs2234767 A/G (Ala → Thr) 100 0.47 0.02
10 rs2234978 T/C (Thr → Thr) 99.5 0.02 1.00
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were also estimated using the Kaplan–Meier method. In 
univariate analyses, treatment outcomes, such as MCR, 
CCR, MMR, MR4.5, LOR, TF, PFS, and OS were com-
pared using log-rank tests. Multivariate analysis was 
performed with variables including age, prior treatment, 
additional cytogenetic abnormalities, disease stage (CP 
versus AP/BC) and significant genotypes in the univari-
ate analyses. The multivariate analyses using Cox’s pro-
portional hazard models were conducted using an enter 
model and a p value for the likelihood ratio test of >0.05.
For validation of the genetic effect, we performed inter-
nal validation using a bootstrap algorithm. Bootstrap is a 
resampling technique which creates bootstrap data sets 
by sampling with replacement. It gave us a nonparamet-
ric maximal likelihood estimate of the prediction error 
and can correct for the bias of the estimate and therefore 
avoid the need for cross-validation. We applied bootstrap 
based on 1000 replications, and the results are presented 
as the bootstrap hazard ratio (HR), confidence intervals 
and p values of the genetic effects. All statistical tests 
were two-sided with the significance level set as 0.05.
The prognostic stratification value was assessed by the 
likelihood ratio test (LRT) using the Cox proportional 
hazard regression model for MR4.5 as the endpoint to 
measure how well the risk score performs in predicting 
future clinical events. The log likelihood ratio test evalu-
ates superiority of a prognostic stratification system over 
another. Two multivariate models were compared: one 
with only clinical risk factors, and another using clinical 
risk factors as well as genotype data. All the above sta-
tistical tests were performed using SAS version 9.1 (SAS 
Institute, Cary NC, USA) and EZR (http://www.jichi.
ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html).
Results
Patient and disease characteristics and imatinib treatment 
outcomes
Patient demographic and disease characteristics are 
presented in Table  2. In total, 187 CML patients were 
included in the study. The median age was 49 years (range 
11–87). One hundred and sixty nine patients (90 %) were 
in CP, 11 (6  %) in AP, and 7 (4  %) in BC. The median 
follow-up time was 41.7  months (range 1–98.1). Inci-
dences of MCR at 6 months, CCR at 12 months, MMR at 
18 months and MR4.5 at 3 years were 43.9, 63.1, 45.3 and 
44.0 % respectively. Of the 187 patients, 53 had evidence 
of treatment failure, and 16 LOR.
Univariate analysis of candidate SNPs in the apoptosis 
pathway
Details of the eight candidate SNPs are summarized in 
Table 1 and Additional file 1: Table S1. There is a strong 
linkage disequilibrium between the SNPs in FAS (r2 = 1; 
rs2234767 and rs1800682), presented in Additional file 1: 
Figure S1.
The patient clinical characteristics, treatment his-
tory prior to imatinib, initial imatinib dose, disease 
stage and sokal risk score all correlated with responses 
to imatinib. In univariate analysis, patients who 
had prior treatment showed a lower probability of 
achieving MCR (p  =  0.009), CCR (p  =  0.016), MMR 
(p = 0.002), and MR4.5 (p = 0.011), and had a shorter 
time to TF (p = 0.039). Patients with a high sokal risk 
score showed a lower probability of achieving CCR 
(p = 0.050) and a shorter time to TF (p = 0.003) (Addi-
tional file 1: Table S2).
The results of univariate analyses for treatment out-
comes with imatinib are presented in Table  3. The GG/
GA versus AA FAS genotypes (rs2234767) showed rates 
of MR4.5 at 5  years of 59.7  ±  4.7  % (49.7–68.3  %) vs 
37.4 ± 10.6 % (16.6–58.3 %) respectively (p value = 0.013, 
Hazard ratio 0.423, 95  % confidence interval [95  % CI 
0.229–0.781]; Fig. 1b). The CC FAS genotype (rs1800682) 
also showed a lower MR4.5 rate than other genotypes 
Table 2 Summary of  patient demographic and  disease 
characteristics as  well as  treatment outcomes in  187 CML 
patients treated with imatinib
AP accelerated phase, BC blastic crisis, CP chronic phase
* Additional cytogenetic abnormalities: t(9; 22; 11) (n = 1); t(7; 9; 22) (n = 1); t(9; 
22; 17) (n = 1); t(9; 22; 19) (n = 1); t(4; 22) with t(17; 20) (n = 1); inv(3) (n = 2); 
der(9) (n = 1); der(9), del(9) (n = 1); del(22q) (n = 1); +der(22) (n = 3); −Y(n = 1); 
+8(n = 1); −12 (n = 1); 92, idemx2(n = 3); 69, XXX with 92, XXXX and 138, 
XXXXXX (n = 1), t(8;9;22) (n = 1); dup(1) (n = 1)
Characteristics Variables No of pts (%)
Gender Female 79 (42)
Male 109 (58)
Age (Years, median, range) 49.0 (11–87)
Follow‑up duration (Months, median, range) 41.7 (0–98.1)
Cytogenetics at diagnosis t(9;22) only 153 (81)
Additional abnormalities* 27 (15)
Unknown 7 (4)









Previous treatment (any) De novo 145 (77.5)
Previously treated 42 (22.5)
Previous treatment prior to 
imatinib
Interferon‑alpha 30 (16.0)
Duration of imatinib therapy Median in months (range) 36.9 (0–98.1)
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(p = 0.032; Table 3 and Fig. 1). The incidence of MR4.5 
at 5  years in the TT/TC FAS genotype (rs1800682) was 
58.8 ± 5.1 % (48.2–68.0 %) vs 42.2 ± 10.0 % (22.1–61.3 %) 
in the CC genotype (HR 0.508, 95  % CI [0.291–0.886]; 
Fig. 1a).
In the case of CASP10 (rs13006529), the TT geno-
type correlated with a lower risk of TF and a longer OS 
than the TA/AA genotype (Table  3). The probability 
of freedom from TF at 5 years in the TT genotype, was 
71.5 ± 4.7 % (61.2–79.5 %), vs 59.6 ± 6.6 % (45.2–71.2 %) 
in the TA or AA genotypes (p = 0.025, HR 0.543, 95 % CI 
[0.317–0.932]; Fig. 2).
Patients with the CC FASLG genotype (rs763110) 
showed a higher MMR rate, and a longer PFS and OS 
compared to the TT/TC genotype (Table  3 and Fig.  3): 
MMR at 18  months of 51.0  ±  5.4  % (39.9–61.0  %) vs 
35.6 ± 5.1 % (25.6–45.7 %), p = 0.017; PFS of 98.7 ± 2.2 % 
(91.0–99.8  %) vs 77.7 ±  6.0  % (63.3–87.0  %), p =  0.001; 
and OS at 5  years of 98.6  ±  2.4  % (90.5–99.8  %) vs 
89.5 ± 4.2 % (78.7–95.0 %) p = 0.020.
In FAS (rs2234978), the TT/TC genotype showed a 
higher rate of MCR (p = 0.026), CCR (p = 0.036), MMR 
(p =  0.050) and MR4.5 (p =  0.011) compared to those 
with the CC genotype (Table 3).
Internal validation using a bootstrap procedure confirmed 
the significance of the correlation between FAS genotype 
and MR4.5
The p value from the bootstrap procedure was signifi-
cant at 0.050 (95 % CI [0.000–0.221]), confirming that the 
Table 3 Summary of results of the univariate analysis for treatment outcomes based on the candidate genotypes in the 
apoptosis pathway
SNP single nucleotide polymorphism, MCR major cytogenetic response, CCR complete cytogenetic response, MMR major molecular response, MR4.5 complete 
molecular response, LOR loss of response, TF treatment failure, PFS progression free survival, OS overall survival, APAF1 apoptotic peptidase activating factor 1, CASP10 
caspase 10, FAS Fas cell surface death receptor, FASLG Fas ligand (TNF receptor superfamily member 6)
** p < 0.01/* p < 0.05




MCR CCR MMR MR4.5 LOR TF PFS OS
APAF1 rs1439123 CC/CT TT 0.803 0.393 0.233 0.085 0.011* 0.323 0.510 0.939
APAF1 rs2288713 GG/TG TT 0.747 0.886 0.617 0.530 0.812 0.992 0.271 0.863
CASP10 rs13006529 AA/TA TT 0.250 0.433 0.513 0.671 0.144 0.025* 0.311 0.019*
FASLG rs763110 TT/TC CC 0.414 0.186 0.017* 0.123 0.145 0.097 0.001** 0.020*
FAS rs1800682 TT/TC CC 0.871 0.354 0.251 0.032* 0.086 0.129 0.428 0.863
FAS rs2229521 GG/GA AA 0.856 0.688 0.748 0.863 0.600 0.384 0.600 0.685
FAS rs2234767 GG/GA AA 0.944 0.259 0.179 0.013* 0.034* 0.093 0.374 0.978
FAS rs2234978 TT/TC CC 0.026* 0.036* 0.050* 0.011* 0.379 0.089 0.409 0.535
Fig. 1 Incidence of MR4.5 based on the FAS (rs1800682) (a) and FAS (rs2234767) (b) genotypes
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FASGG/GA genotype (rs2234767) was associated with 
a higher MR4.5 rate compared to the AA genotype (HR 
0.431, 95 % CI [0.219–0.682]; Table 4).
Multivariate analyses confirming FAS genotype 
(rs2234767) as an independent predictor for MR4.5
Multivariate analysis was performed in order to confirm 
that the candidate SNP is an independent risk factor for 
clinical outcomes after adjustment for other clinical risk 
factors including age, prior treatment, additional cytoge-
netic abnormalities and disease stage.
Analysis revealed that the patients with the FAS 
AA genotype (rs2234767) showed a lower probabil-
ity of achieving MR4.5 (p =  0.019, HR 0.43, 95  % CI 
[0.22–0.87]) than those with the GG/GA genotype, 
and that those with the CC genotype (rs2234978) 
had a lower probability of MR4.5 (p = 0.003 HR 0.45, 
95 % CI [0.26–0.77]) than those with the CC genotype 
(Table 5).
Patients with the CASP10 TT genotype (rs13006529) 
had a lower probability of freedom from TF (p = 0.049 
HR 0.57, 95 % CI [0.32–0.99]) and a better OS (p = 0.050 
HR 0.25, 95 % CI [0.06–1.00]) than those with the AA/
TA genotype. In addition, patients with the FASLG CC 
genotype (rs763110) had a better PFS (p  =  0.003 HR 
0.04, 95 % CI [0.01–0.36]) and OS (p = 0.046 HR 0.12, 
95 % CI [0.01–0.97]) than those with the TT/TC geno-
type. History of treatment prior to imatinib was a risk 
factor for TF (p = 0.040 HR 1.94, 95 % CI [1.03–3.67]) 
and MMR (p  =  0.007 HR 0.44, 95  %  CI [0.24–0.80]; 
Table 5).
The incorporation of genotype in addition to clinical 
factors in multivariate analysis improved the prognostic 
stratification power for MR4.5
We attempted to answer the question of whether the 
addition of genotype data could enhance prognostic 
stratification. Two multivariate models were compared: 
one with clinical risk factors alone, and another with 
additional genotype data. The log likelihood ratio test for 
MR4.5 showed a significant difference between the two 
models in favor of the model including genotype data 
(p = 0.006; Additional file 1: Table S3).
Discussion
Imatinib is a specific inhibitor of the bcr-abl1 fusion 
protein and is an example of successful targeted therapy 
[29]. However, it appears that the clinical response of 
imatinib relies on the genetic background of a patient. 
In this study we focused on eight SNPs involved in the 
apoptosis pathway. Results showed that: (1) the GG/
GA FAS genotype (rs2234767) showed a higher MR4.5 
rate at 5  years of 59.7  % compared to the AA genotype 
(37.4 %, p = 0.013); (2) an internal validation procedure 
confirmed that FAS (rs2234767) correlates with MR4.5 
using multiple replications with a bootstrap algorithm 
(p  =  0.050); (3) multivariate analyses confirmed that 
FAS genotype (rs2234767) is an independent predictor 
for MR4.5 even after taking into account other clinical 
risk factors including age, prior treatment, additional 
cytogenetic abnormality and disease stage (p  =  0.019, 
HR 0.43, 95  % CI [0.22–0.87]). Recent advances in the 
CML treatment suggested around 40  % of patients can 
achieve treatment free remission without requiring active 
CML treatment even after stopping TKI in the patients 
attained deeper molecular response (defined as 4.5 log 
reduction of bcr-abl1 transcript or deeper) for 2 years or 
longer following imatinib therapy for 5  years or longer. 
This finding emphasized clinical importance of MR4.5 
achievement as a relevant milestone for TKI discontinua-
tion attempt [30].
Binding of Fas ligand (FasL) to its membrane recep-
tor Fas-R induces apoptosis via a typical death receptor 
signaling pathway. The trimerization of Fas-R upon the 
binding with FasL recruits and subsequently activates 
Caspase 8 and 10, and these initiator caspases trigger 
apoptosis by activating executive Caspase 3 directly, 
or by activating Bid and releasing cytochrome C from 
mitochondria. The FasL/Fas-R signaling pathway plays 
an important role in both physiological and pathologi-
cal conditions [31]. Fas-R is expressed constitutively in 
CD34+ cells in CML patients. Fas-R triggering results in 
a decreased proliferation rate due to apoptosis of clono-
genic cells [32].
Fig. 2 Probability of freedom from treatment failure based on the 
CASP10 genotype (13006529)
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The Fas-mediated apoptosis pathway is important 
in imatinib’s mechanism of action. The FAS genotype 
(rs2234767) showed a significant and independent asso-
ciation with the achievement of MR4.5. Furthermore the 
FAS genotype showed a greater correlation with MR4.5 
than other clinical parameters, probably because the 
Fas-mediated apoptosis pathway is more significant in 
CD34+/CD38− LSCs compared to differentiated hemat-
opoietic cells, a parameter reflecting LSC burden after 
imatinib therapy.
The two SNPs in FAS, rs2234767 (GG/GA vs AA) and 
(rs1800682; TT/TC vs CC) that had a strong association 
with MR4.5 are functional polymorphisms in the FAS 
promoter region. The A to G transition at rs1800682 
Fig. 3 Differences in MMR (a), PFS (b) and OS (c) based on the FASLG genotype (rs763110)
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in the enhancer region, modulates the signal trans-
ducer and activator of transcription (STAT-1), thus 
diminishing promoter activity and resulting in down-
regulation of Fas expression [33]. The G to A substitu-
tion at rs2234767 in the silencer region of the FAS gene 
is reported to be associated with cancer risk, so that 
the AA genotype increases the risk of cancer, while the 
G-allele is a protective factor [34]. In this study, the G 
allele increased the rate of MR4.5 compared to the A 
allele. This suggests that the G-allele may result in higher 
Fas expression that correlates with a better response to 
imatinib therapy.
Other genotypes also showed potential correlations 
with clinical outcomes of imatinib therapy. The CASP10 
genotype (rs13006529) which encodes an immediate 
downstream apoptotic initiator CASP10 was associated 
with treatment failure. Although this SNP lacks func-
tional validation it is known to be significantly associated 
with cancer risk [35]. Also, SNPs in FASLG, rs763110 (CC 
vs TC  +  TT) showed a strong association with MMR, 
PFS and OS. These SNPs are located within a putative 
binding motif in the CAAT/enhancer-binding protein β 
transcription factor. Higher expression of FASLG is asso-
ciated with the C allele compared to the T allele, thus the 
polymorphism may affect FasL expression and therefore 
FasL/Fas signaling [36].
One limitation of this study is that we only ana-
lyzed the association between these SNPs and out-
comes of imatinib in Korean patients. As the genetic 
backgrounds among different ethnic populations may 
differ significantly, other SNPs in these genes and 
others involved in the apoptosis pathways may also 
be relevant to the efficacy of imatinib treatment in 
those groups and would need to be investigated fur-
ther. In conclusion, treatment outcomes of imatinib 
therapy in CML patients correlate well with genetic 
variants in the apoptosis pathway. The Fas/FasL sign-
aling pathway may represent the major pathway that 
mediates apoptosis in CML treated with imatinib. The 
response to imatinib, particularly MR4.5, was strongly 
associated with the FAS genotype (rs2234767) which 
was confirmed in multivariate analyses and also vali-
dated using a Bootstrap procedure. These apoptosis-
associated SNPs can be used as predictive/prognostic 
markers for imatinib treatment in CML patients allow-
ing more risk adaptive strategies in patients at risk of 
treatment failure. Furthermore, additional strategies 
that enhance the Fas/FasL signaling pathway with 
imatinib may increase its clinical efficacy. The weak-
ness of the present study is lack of replication data 
using an independent set of patients. Accordingly, 
validation of the current results will be needed in an 
independent set of patients with different ethnicities 
in order to reach clear conclusion on the issue. Fur-
ther study is also necessary to identify the functional 
aspects of these SNPs in relation to the mechanism of 
action of imatinib, especially in LSCs and to identify 
variations in different ethnic groups.
Conclusions
In summary, we analyzed the association between 
SNPs in the Fas/FasL signaling pathway and treatment 
outcomes including molecular response with 4.5 log 
reduction (MR4.5), following imatinib therapy in 187 
Table 4 Internal validation using a Bootstrap procedure 
with 1000 replications
MCR major cytogenetic response, CCR complete cytogenetic response, MMR 
major molecular response, MR4.5 complete molecular response, LOR loss of 
response, TF treatment failure, PFS progression free survival, OS overall survival, 
HNF4A hepatocyte nuclear factor 4, alpha, APAF1 apoptotic peptidase activating 
factor 1, FAS Fas cell surface death receptor, FASLG Fas ligand (TNF receptor 
superfamily member 6)
* P ≤ 0.05
Parameter Gene SNP ID Bootstrap p value (95 % CI)
MCR FAS rs2234978 0.138 (0.000–0.605)
CCR FAS rs2234978 0.187 (0.000–0.727)
MMR FASLG rs763110 0.065 (0.000–0.351)
FAS rs2234978 0.178 (0.000–0.762)
MR4.5 FAS rs1800682 0.497 (0.053–0.951)
FAS rs2234767 0.050 (0.000–0.221)*
FAS rs2234978 0.073 (0.000–0.345)
LOR APAF1 rs1439123 0.142 (0.000–0.749)
FAS rs2234767 0.169 (0.000–0.783)
TF CASP10 rs13006529 0.102 (0.000–0.563)
PFS FASLG rs763110 0.365 (0.003–0.992)
OS CASP10 rs13006529 0.162 (0.002–0.991)
FASLG rs763110 0.424 (0.017–0.994)
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Table 5 Results of multivariate analyses










 FAS (rs2234978) CT/TT CC 0.026 0.062 0.52 (0.26–1.03)
 Age, continuous – – 0.748 0.920 1.00 (0.99–1.01)
 Prior treatment No Yes 0.009 0.060 0.56 (0.30–1.03)
 ACA Absent Present 0.128 0.560 0.85 (0.50–1.45)
 Disease stage AP/BC CP 0.450 0.190 1.98 (0.72–5.46)
CCR
 FAS (rs2234978) CT/TT CC 0.036 0.100 0.56 (0.28–1.12)
 Age, continuous – – 0.796 0.910 0.99 (0.98–1.01)
 Prior treatment No Yes 0.016 0.074 0.57 (0.31–1.05)
 ACA Absent Present 0.496 0.330 0.77 (0.45–1.30)
 Disease stage AP/BC CP 0.399 0.060 2.48 (0.96–6.38)
MMR
 FAS (rs2234978) CT/TT CC 0.050 0.022* 0.53 (0.30–0.91)
 FASLG (rs763110) CT/TT CC 0.017 0.079 1.42 (0.96–2.11)
 Age, continuous – – 0.670 0.880 0.99 (0.98–1.01)
 Prior treatment No Yes 0.002 0.007** 0.44 (0.24–0.80)
 ACA Absent Present 0.097 0.490 0.81 (0.44–1.48)
 Disease stage AP/BC CP 0.235 0.062 2.48 (0.96–6.44)
MR4.5
 FAS (rs2234767) GA/GG AA 0.013 0.019* 0.43 (0.22–0.87)
 FAS (rs2234978) CT/TT CC 0.011 0.003** 0.45 (0.26–0.77)
 Age, continuous – – 0.911 0.470 0.99 (0.98–1.01)
 Prior treatment No Yes 0.011 0.051 0.50 (0.25–1.00)
 ACA Absent Present 0.110 0.930 0.97 (0.46–2.02)
 Disease stage AP/BC CP 0.316 0.110 3.17 (0.76–13.17)
LOR
 APAF1 (rs1439123) TT CT/CC 0.011 0.174 0.36 (0.08–1.57)
 FAS (rs2234767) GA/GG AA 0.034 0.177 2.21 (0.70–7.02)
 Age, continuous – – 0.875 0.99 (0.96–1.03)
 Prior treatment No Yes 0.062 0.538 1.47 (0.43–5.06)
 ACA Absent Present 0.973 0.918 1.08 (0.24–4.89)
 Disease stage AP/BC CP 0.432 0.607 1.77 (0.20–15.43)
TF
 CASP10 (rs13006529) TA/AA TT 0.025 0.049* 0.57 (0.32–0.99)
 Age, continuous – – 0.978 0.869 0.99 (0.97–1.02)
 Prior treatment No Yes 0.039 0.040* 1.94 (1.03–3.67)
 ACA Absent Present 0.257 0.483 1.31 (0.61–2.81)
 Disease stage AP/BC CP 0.001 0.093 0.47 (0.20–1.13)
PFS
 FASLG (rs763110) CT/TT CC 0.001 0.003** 0.04 (0.01–0.36)
 Age, continuous – – 0.765 0.260 0.98 (0.94–1.02)
 Prior treatment No Yes 0.235 0.053 3.28 (0.98–10.90)
 ACA Absent Present 0.093 0.018* 4.36 (1.29–14.71)
 Disease stage AP/BC CP 0.873 0.251 3.58 (0.41–31.68)
OS
 CASP10 (rs13006529) TA/AA TT 0.019 0.050* 0.25 (0.06–1.00)
 FASLG (rs763110) CT/TT CC 0.020 0.046* 0.12 (0.01–0.97)
 Age, continuous – – 0.787 0.300 0.97 (0.92–1.02)
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Korean CML patients. We identified the Fas genotype 
(rs2234767) as a potential independent surrogate for 
MR4.5 in imatinib therapy. Genetic testing and some 
specific SNPs are helpful for drug selection for CML 
patients.
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